Latest pharma updates on Neurology
FDA Approves Novartis Gene Therapy Itvisma for Spinal Muscular Atrophy (SMA)
The U.S. FDA has granted Novartis' gene therapy Itvisma approval for the treatment of spinal muscular atrophy (SMA)...
Read Full StoryThe U.S. FDA has granted Novartis' gene therapy Itvisma approval for the treatment of spinal muscular atrophy (SMA)...
Read Full Story